UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.

Non-viral gene therapies may hold potential to overcome some safety, pricing and manufacturing hurdles linked to viral alternatives.

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

Arrowhead Pharmaceuticals has received approval from the Australian TGA for Redemplo to treat familial chylomicronemia syndrome.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.